Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company that develops and commercializes innovative therapeutics for neurodegenerative diseases. The company's clinical-stage programs are advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications. Neuraltus collaborates with global ALS specialists and patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease. The company's goal is to provide treatment for neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, and lysosomal storage disorders.